Who is sponsoring NCT00450515?

NCT00450515 is sponsored by Alliance for Clinical Trials in Oncology.

What condition does NCT00450515 study?

NCT00450515 studies Breast Cancer.

What drugs are being tested in NCT00450515?

Interventions: capecitabine, vinflunine.

What is the status of NCT00450515?

NCT00450515 is currently WITHDRAWN.

Last reviewed 2016-12-02 · How we verify

Phase II Trial of Vinfluinine and Capecitabine in Previously Treated Metastatic Breast Cancer

NCT00450515 Phase 2 WITHDRAWN

RATIONALE: Drugs used in chemotherapy, such as vinflunine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving vinflunine together with capecitabine works in treating patients with previously treated metastatic breast cancer.

Details

Lead sponsor	Alliance for Clinical Trials in Oncology
Phase	Phase 2
Status	WITHDRAWN
Start date	2007-03
Completion	2009-01

Conditions

Breast Cancer

Interventions

capecitabine
vinflunine

Primary outcomes

Confirmed tumor response — Up to 10 years